ASC22 (Envafolimab) is a subcutaneously administered single-domain antibody against PD-L1 and has the potential to restore virus-specific immune responses in patients with chronic viral infection
Nirsevimab is the first investigational immunization designed to protect all infants across the RSV season with a single dose
The plan is to advance innovative therapies to drug-resistant cancers
To lay a technological foundation for developing exosome-based medicines and cosmetic products for dermatitis treatment
Ahead of International Thalassemia Day on 8th May, medical professionals and representatives of patient bodies participated in a virtual discussion on the current situation of Thalassemia management in India
If granted, Nuvaxovid would be the first protein-based Covid-19 vaccine option for adolescents in Australia and New Zealand
The production suspension impacts commercial and clinical trial supply
The FDA has determined that the known and potential benefits of the vaccine for the prevention of Covid-19 outweigh the known and potential risks for individuals 18 years of age and older for whom other authorized or approved vaccines are not accessible
The companies expect to complete the submission of the NDA for treatment of MDD in the second half of 2022; associated filing for postpartum depression is anticipated in the first half of 2023
The USFDA approval in AS marks the fifth indication for Rinvoq in chronic immune-mediated diseases
Subscribe To Our Newsletter & Stay Updated
